Search

Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens. People living with human immunodeficiency virus (PLWH) might be at higher risk for COVID-19 progression; however, information about the impact of tenofovir on COVID-19 clinical outcomes remains controversial. The COVIDARE is a prospective observational multicentric study in Argentina. PLWH with COVID-19 were enrolled from September 2020 to mid-June 2022. Patients were stratified according to baseline ART into those with tenofovir (TDF or TAF) and those without. Univariate and multivariate analyses were performed to evaluate the impact of tenofovir vs. non-tenofovir-containing regimens on major clinical outcomes. Of the 1155 subjects evaluated, 927 (80%) received tenofovir-based ART (79% TDF, 21% TAF) whilst the remaining population was under non-tenofovir regimens. The non-tenofovir group had older age and a higher prevalence of heart and kidney disease. Regarding the prevalence of symptomatic COVID-19, tomographic findings, hospitalization, and mortality, no differences were observed. The oxygen therapy requirement was higher in the non-tenofovir group. In the multivariate analyses, a first model with adjustment for viral load, CD4 T-cell count, and overall comorbidities showed that oxygen requirement was associated with non-tenofovir ART. In a second model with adjustment by chronic kidney disease, tenofovir exposure was not statistically significant.

An epidemic of dengue virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infections occurred in Argentina during 2020. We describe the clinical characteristics and outcomes in a cohort of patients hospitalized because of co-infection. We retrospectively identified 13 patients from different hospitals in Buenos Aires who had confirmed infection with SARS-CoV-2 and dengue virus and obtained clinical and laboratory data from clinical records. All patients had febrile disease when hospitalized. Headache was a common symptom. A total of 8 patients had respiratory symptoms, 5 had pneumonia, and 3 had rash. Nearly all patients had lymphopenia when hospitalized. No patients were admitted to an intensive care unit or died during follow up. Co-infection with SARS-CoV-2 and dengue virus can occur in patients living in areas in which both viruses are epidemic. The outcome of these patients did not seem to be worse than those having either SARS-CoV-2 or dengue infection alone.

BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) producing COVID-19 disease and Dengue are both epidemic in Argentina. To date, most cases of both virus are from Buenos Aires city. Here we describe the clinical characteristics and follow up from a cohort patients coinfected with dengue and SARS-CoV-2 in Buenos Aires. METHODS: We retrospectively identified patients from different Buenos Aires area hospitals who were admitted with confirmed infection with Dengue Virus and SARS-CoV-2. Clinical data were obtained through review of medical records. Patients had at least 3 weeks follow-up. RESULTS: Thirteen patients were identified. The median age was 37 years old, most of them didn't had any comorbidity, almost half were females, and all had febrile disease at presentation The median duration of fever was 7 days. Headache was a common symptom among coinfected subjects. A total of eight patients had respiratory symptoms. Five patients had pneumonia. Three patients had rash that appear early in the course of the disease. Two of these patients had concomitant pneumonia and rash. Almost all patients had Lymphopenia at presentation and thrombocytopenia in almost half of them. No patients required ICU or died during the follow up. CONCLUSION: SARS-CoV2 and Dengue can produce coinfections in patients living in areas where both virus are epidemic. The outcome of these patients does not seem to be worse than having either SARS-Cov2 or Dengue alone. FUNDING STATEMENT: The authors stated that this article doesn´t have funding sources. DECLARATION OF INTERESTS: MES is a consultant to Basilea and the principal investigator for Argentina NIH grant UM1AI104681; all others have no interests to declare ETHICS APPROVAL STATEMENT: This study was approved by the Ethic Committee of Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina.